Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Wedbush raised their FY2017 earnings per share (EPS) estimates for shares of Xencor in a research note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($1.02) for the year, up from their prior estimate of ($1.16). Wedbush currently has a “Outperform” rating and a $29.00 price target on the stock. Wedbush also issued estimates for Xencor’s Q2 2018 earnings at ($0.42) EPS, FY2018 earnings at ($1.71) EPS, FY2019 earnings at ($1.90) EPS, FY2020 earnings at $1.00 EPS and FY2021 earnings at $0.81 EPS.

XNCR has been the topic of several other reports. Zacks Investment Research downgraded Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Canaccord Genuity restated a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $29.33.

COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/fy2017-eps-estimates-for-xencor-inc-nasdaqxncr-lifted-by-analyst.html.

Shares of Xencor (XNCR) traded up 0.09% on Friday, reaching $21.30. The company’s stock had a trading volume of 6,443 shares. The company has a 50 day moving average of $22.64 and a 200 day moving average of $23.06. The stock’s market capitalization is $999.52 million. Xencor has a 1-year low of $18.45 and a 1-year high of $29.38.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. The company had revenue of $13.34 million for the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%.

In related news, Director Bruce L. A. Carter sold 12,400 shares of the company’s stock in a transaction on Friday, May 26th. The stock was sold at an average price of $22.19, for a total value of $275,156.00. Following the completion of the transaction, the director now directly owns 83,344 shares in the company, valued at $1,849,403.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John S. Stafford III bought 1,500 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The stock was acquired at an average price of $19.67 per share, with a total value of $29,505.00. The disclosure for this purchase can be found here. Insiders sold 34,766 shares of company stock valued at $739,408 over the last quarter. Insiders own 4.03% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA raised its position in Xencor by 0.4% in the first quarter. Primecap Management Co. CA now owns 5,793,356 shares of the biopharmaceutical company’s stock valued at $138,577,000 after buying an additional 24,534 shares during the last quarter. Vanguard Group Inc. raised its position in Xencor by 5.2% in the first quarter. Vanguard Group Inc. now owns 1,611,115 shares of the biopharmaceutical company’s stock valued at $38,537,000 after buying an additional 79,445 shares during the last quarter. Redmile Group LLC raised its position in Xencor by 59.9% in the first quarter. Redmile Group LLC now owns 1,592,526 shares of the biopharmaceutical company’s stock valued at $38,093,000 after buying an additional 596,426 shares during the last quarter. State Street Corp raised its position in Xencor by 17.5% in the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock valued at $23,751,000 after buying an additional 148,136 shares during the last quarter. Finally, Norges Bank acquired a new position in Xencor during the fourth quarter valued at approximately $15,601,000. Hedge funds and other institutional investors own 74.12% of the company’s stock.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.